The Weinbach Group, Inc. | Agency Profile, Contacts, AOR, Client Relationships

See Winmo sales intelligence in action

B2B Media Opps: Pharmaceutical co Cutanea Life Sciences launches new product, taps agency to assist

press release).

Spend will likely be high since Xepi is the first impetigo treatment approved by the FDA in more than a decade. Thus, sellers should contact Weinbach for last minute dollars tied to the launch. Cutanea targets dermatologists, though Xepi in particular will target pediatric dermatologists and pediatricians since impetigo is highly prevalent among infants and young children (it affects several million young children each year). They do not have a top spending period, so reach out year round.

If you have high reach among dermatologists, you can also reach out for other new Cutanea products. Psoriasis has FDA approval and will likely launch in the next 12 months. They have numerous other products in development, all of which can be viewed here, that will likely launch in the next few years.

There is no spend or channel information available for Cutanea, but expect work to fall in line with Weinbach's medical advertising agenda. They use content marketing (blogs, articles and whitepapers), social media (owned and paid), video, paid search, SEO, email marketing, banner advertising, influencer marketing, direct mail, outdoor and print. All of this is based on analytics like behavioral, demographic and geo-targeting.

Agency & martech readers -- Xepi has all their bases covered with this new hire, so you can't secure more work there. However, you may be able to pick up launch work for the other products Cutanea has in development. Expect competition from Weinbach. Leverage their medical advertising strategy in your pitches. (Their medical advertising strategy can be summed up with doctors are people, too, so keep it simple, use bold imagery and use an integrated media mix.)